Schneider-Thoma Johannes, Dong Shimeng, Efthimiou Orestis, Siafis Spyridon, Hansen Wulf Peter, Scheuring Elfriede, Möhrmann Karl Heinz, Leucht Stefan
Partner Site München/Augsburg, German Center for Mental Health (DZPG), Munich, Germany.
TUM School of Medicine and Health, Klinikum rechts der Isar, Department of Psychiatry and Psychotherapy, Technical University of Munich, Munich, Germany.
F1000Res. 2025 Feb 11;13:973. doi: 10.12688/f1000research.154742.2. eCollection 2024.
Sexual dysfunctions are common yet underreported side effects of antipsychotics for schizophrenia, affecting 30-80% of treated individuals. These side effects can severely impact social interactions and treatment adherence for individuals with schizophrenia, but comprehensive comparative evidence assessing the risk profiles of different antipsychotics is lacking. This study aims to address this gap using network meta-analysis that integrates data from both randomized-controlled trials (RCTs) and non-randomized studies (NRS).ProtocolThis systematic review will include both RCTs and NRS focusing on participants with schizophrenia or schizophrenia-like psychoses, without restrictions on symptoms, gender, ethnicity, age, or setting. For interventions, all second-generation antipsychotics will be included. The primary outcome will be the occurrence of at least one sexual adverse event of any kind. Secondary outcomes will be the occurrence of any sexual adverse event evaluated in men and women separately, and any adverse event related to the three phases of sexual response cycle separately: desire (e.g. libido, sexual thoughts), arousal (e.g. erection, lubrication) and orgasm (e.g. ejaculation, anorgasmia), and any adverse effect related to breast dysfunction and menstruation irregularities. Study selection and data extraction will be performed independently by two reviewers. The Cochrane Risk of Bias tool 1 and ROBINS-I will be employed to evaluate the risk of bias for RCTs and NRS, respectively. Single-arm meta-analysis of proportions will synthesize the average frequency of sexual adverse events in treated participants. Pairwise and network meta-analysis of RCTs and NRS will be used to evaluate comparative tolerability. Subgroup and sensitivity analyses will explore possible heterogeneity in results and validate the findings' robustness. The quality of the evidence will be evaluated using GRADE.
This study will provide vital insights into the sexual side effects of antipsychotics by combining evidence from clinical trials and real-world practice, facilitating better decision-making in choosing the optimal antipsychotic for individuals.
性功能障碍是抗精神病药物治疗精神分裂症常见但报告不足的副作用,影响30%-80%的接受治疗者。这些副作用会严重影响精神分裂症患者的社交互动和治疗依从性,但缺乏评估不同抗精神病药物风险概况的全面比较证据。本研究旨在通过整合随机对照试验(RCT)和非随机研究(NRS)数据的网络荟萃分析来填补这一空白。
方案
本系统评价将纳入针对精神分裂症或精神分裂症样精神病患者的RCT和NRS,对症状、性别、种族、年龄或环境不做限制。对于干预措施,将纳入所有第二代抗精神病药物。主要结局将是至少发生一种任何类型的性不良事件。次要结局将分别是男性和女性中评估的任何性不良事件的发生情况,以及与性反应周期三个阶段分别相关的任何不良事件:欲望(如性欲、性想法)、唤起(如勃起、润滑)和高潮(如射精、性高潮缺失),以及与乳房功能障碍和月经不调相关的任何不良影响。研究选择和数据提取将由两名评审员独立进行。将分别使用Cochrane偏倚风险工具1和ROBINS-I评估RCT和NRS的偏倚风险。单臂比例荟萃分析将综合治疗参与者中性不良事件的平均频率。RCT和NRS的成对和网络荟萃分析将用于评估比较耐受性。亚组分析和敏感性分析将探索结果中可能存在的异质性并验证研究结果的稳健性。将使用GRADE评估证据质量。
本研究将通过结合临床试验和实际临床实践的证据,为抗精神病药物的性副作用提供重要见解,有助于在为个体选择最佳抗精神病药物时做出更好的决策。